Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at Wells Fargo & Company

Keros Therapeutics (NASDAQ:KROS) had its target price reduced by equities researchers at Wells Fargo & Company from $23.00 to $20.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of 65.43% from the stock’s current price.

KROS has been the topic of a number of other reports. TD Cowen upgraded shares of Keros Therapeutics to a “hold” rating in a report on Friday, December 19th. Bank of America boosted their price objective on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, November 28th. Wedbush raised their target price on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research note on Thursday, November 6th. Oppenheimer reiterated an “outperform” rating and set a $27.00 price target (up from $23.00) on shares of Keros Therapeutics in a report on Wednesday, November 12th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Keros Therapeutics in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Keros Therapeutics has an average rating of “Hold” and an average price target of $21.86.

Keros Therapeutics Stock Down 12.2%

Shares of NASDAQ:KROS traded down $1.68 during midday trading on Thursday, reaching $12.09. The company had a trading volume of 309,971 shares, compared to its average volume of 331,639. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $22.55. The stock has a market cap of $368.38 million, a PE ratio of 7.85 and a beta of 0.87. The business’s 50 day moving average price is $17.81 and its 200 day moving average price is $17.10.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.37). The company had revenue of $0.39 million for the quarter, compared to analyst estimates of $3.66 million. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The business’s revenue for the quarter was down 87.2% on a year-over-year basis. During the same period last year, the company posted ($1.14) earnings per share. On average, research analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds have recently made changes to their positions in the stock. Financial Management Professionals Inc. acquired a new position in shares of Keros Therapeutics during the fourth quarter valued at about $29,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after buying an additional 1,166 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after buying an additional 1,888 shares during the last quarter. Farther Finance Advisors LLC bought a new position in Keros Therapeutics during the 3rd quarter valued at $47,000. Finally, SG Americas Securities LLC bought a new stake in shares of Keros Therapeutics in the 3rd quarter worth $103,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.